Related Experiment Video
Updated: Apr 18, 2026
Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
Published on: February 7, 2021
Multi-platform lung tumors profiling identifies actionable targets and unveils series of uncommon/rare diseases
1Laboratory of Biochemistry and Genetics Pulmonology Unit, Department of Molecular Medicine,University and Fondazione IRCCS, Policlinico San Matteo di Pavia, Pavia, Italy - G.Stella@smatteo.pv.it.
Abstract:
Lung cancer is characterized by a number of genetic alterations, of which a proportion is still unknown. Nevertheless numerous pathogenetically important driver changes have been already been detected in a substantial fraction of patients and translated into a system to improve detection and outcome of the disease. In this scenario, the Lung Cancer Mutation Consortium developed an ambitious project aimed to perform on large scale the molecular profile of lung adenocarcinoma in order to identify actionable targets. The review analyses the paper - recently published showing study findings- taking into account if the car and not the driver matters in lung cancer precision management.
Insights
Researchers analyzed lung adenocarcinoma molecular profiles to find new targets for precision medicine. The study questions whether the tumor
Area of Science:
- Oncology
- Genetics
- Molecular Biology
Background:
- Lung cancer exhibits numerous genetic alterations, with some still unidentified.
- Key driver mutations are recognized in many lung adenocarcinoma patients, guiding treatment strategies.
Purpose of the Study:
- To conduct large-scale molecular profiling of lung adenocarcinoma.
- To identify actionable therapeutic targets for lung cancer management.
Main Methods:
- Analysis of molecular profiles from a significant number of lung adenocarcinoma patients.
- Review of a recently published study detailing these findings.
Main Results:
- Identification of numerous genetic alterations in lung adenocarcinoma.
- Discovery of actionable targets for improved lung cancer detection and outcomes.
Conclusions:
- The study provides insights into the molecular landscape of lung adenocarcinoma.
- It evaluates the impact of molecular profiling on precision cancer management.
